
Catalyst Crew Technologies Corp.
100
Recent company developments include establishing a Venezuelan telehealth subsidiary, updates on capital structure and CEO equity restructuring, participation in HLTH Europe 2026, regulatory and deployment updates for its telehealth platform in Venezuela, appointment of a Chief Operating Officer, and the initial launch of its telehealth platform in April 2026.
- Catalyst Crew Technologies established LataMed AI VE, C.A. to support Venezuelan telehealth operations in May 2026 [N1][S1].
- The company provided a capital structure update regarding CEO equity restructuring in April 2026 [S1].
- Catalyst Crew Technologies announced attendance at HLTH Europe 2026 in April 2026 [S1].
- The company provided updates on regulatory and initial deployment activities for its telehealth platform in Venezuela in April 2026 [S1].
- Vilma Casanova was appointed as Chief Operating Officer in April 2026 [S1].
- Catalyst Crew Technologies announced the initial launch of its telehealth platform in April 2026 [S1].
Catalyst Crew Technologies Corp. is a development-stage company incorporated in Nevada, focusing on artificial intelligence-enabled healthcare technology solutions. The company’s business strategy centers on developing an AI healthcare analytics platform incorporating machine learning and data analytics to support clinical decision-making and healthcare delivery optimization. Key technologies under development include CardioAI, PulmoAI, and NeuroAI, targeting cardiovascular, pulmonary, and neurological clinical domains respectively. The company also aims to develop a technology-enabled healthcare services coordination model to facilitate patient engagement and care coordination, including telehealth and in-person care models. Operations are conducted through a wholly-owned Venezuelan subsidiary as part of a Latin American strategy. The company has not yet generated revenue and remains in the development stage, with initial development and strategic planning activities commencing after a change in control in February 2026. The company’s intellectual property was acquired from its CEO and assigned to its Venezuelan subsidiary. The company faces significant regulatory, economic, and political risks related to operating in Venezuela and the healthcare AI industry’s competitive and regulatory environment.
Catalyst Crew Technologies Corp. is a development-stage AI healthcare technology company focused on building an AI-enabled healthcare analytics platform and a technology-enabled healthcare services coordination model primarily targeting Latin American markets, especially Venezuela. The company has not generated revenue and remains in early development stages. Financial disclosures as of September 30, 2026, show intangible assets of $7.8 million, current liabilities of $829,189, no current assets or cash, and a net loss of $58,108 for the quarter. The company faces significant risks including regulatory, economic, and political challenges in Venezuela, dependence on key personnel and intellectual property acquired from its CEO, and the competitive, rapidly evolving healthcare AI industry. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The company’s focus on AI-enabled healthcare analytics and services coordination addresses growing demand for data-driven clinical decision support and healthcare delivery optimization, particularly in underserved Latin American markets. Its modular AI platform targeting multiple clinical domains could provide differentiated solutions if successfully developed and commercialized. Establishing operations through a Venezuelan subsidiary may enable localized market penetration and strategic partnerships. Recent operational milestones such as launching a telehealth platform and appointing key executives indicate progress in execution.
The company remains in the development stage with no revenue and a history of losses, facing substantial risks including its ability to secure additional financing to continue operations. Its dependence on intellectual property acquired from its CEO and the concentration of ownership pose governance and operational risks. Operating in Venezuela exposes the company to significant economic, regulatory, and political uncertainties that may impede business development and commercialization. The highly competitive and rapidly changing healthcare AI industry presents risks of technological obsolescence and regulatory hurdles that could limit market acceptance.
Catalyst Crew Technologies Corp. operates in the highly specialized and rapidly evolving field of AI-enabled healthcare technology with a focus on Latin American markets, particularly Venezuela. Its moat is primarily based on its proprietary AI healthcare analytics platform and technology-enabled healthcare services coordination model under development, as well as intellectual property acquired from its CEO. However, the company is in early development stages without commercialized products or revenue, and faces significant risks including regulatory challenges, competitive pressures from established and emerging healthcare technology firms, and operational risks related to its geographic focus. The company’s control by a single major shareholder and its early-stage status limit its current competitive advantages.
• Development Stage and Lack of Revenue: The company has not generated revenue and remains in early development stages, with a history of losses and substantial doubt about its ability to continue as a going concern without additional financing.
• Geopolitical and Economic Risks in Venezuela: Operations through a Venezuelan subsidiary expose the company to economic instability, currency controls, regulatory uncertainty, political developments, and potential limitations on repatriation of funds.
• Dependence on Key Personnel and Intellectual Property: The company relies heavily on its CEO who controls key intellectual property acquired from him, creating risks related to ownership disputes and loss of key personnel.
• Competitive and Rapidly Evolving Industry: The healthcare AI industry is highly competitive with rapid technological changes, regulatory complexity, and established competitors with greater resources, posing risks to the company’s ability to develop and commercialize competitive products.
• Regulatory and Compliance Risks: The company’s operations and technology development are subject to complex and evolving healthcare, data privacy, and AI regulations that may vary by jurisdiction and require significant resources to comply with.
Business trends: Development of AI healthcare analytics and services coordination platforms targeting Latin American healthcare markets, with initial telehealth platform deployment in Venezuela.
Execution milestones: Acquisition and internal assignment of intellectual property, establishment of Venezuelan subsidiary, appointment of key executives, and initial telehealth platform launch.
Key risks: Early-stage development with no revenue, financing dependency, geopolitical and regulatory challenges in Venezuela, reliance on key intellectual property and personnel, and competitive industry dynamics.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Catalyst Crew Technologies Corp. is a development-stage technology company focused on AI-enabled healthcare technology solutions as of 2026-11-13 [S1].
- The company is developing an AI healthcare analytics platform and a technology-enabled healthcare services coordination model to support clinical decision-making, patient management, and healthcare delivery optimization [S1].
- The AI platform includes technologies named CardioAI, PulmoAI, and NeuroAI targeting cardiovascular, pulmonary, and neurological clinical domains respectively, all under development and not yet commercialized [S1].
- The company has not generated revenue from its current business operations and remains in the development stage as of 2025-12-31 [S1].
- Operations are conducted through a wholly-owned Venezuelan subsidiary, Inversiones Long 33, C.A., as part of a Latin American strategy [S1].
- The company acquired intellectual property related to its AI healthcare platform from its CEO in February 2026 and assigned these assets to its Venezuelan subsidiary in April 2026 [S1].
- The company’s strategy focuses on healthcare markets in Latin America, initially Venezuela, with plans for technology licensing, service delivery, and strategic partnerships, but no commercial agreements are finalized [S1].
- The company faces significant regulatory, economic, and political risks related to operating in Venezuela, including currency controls and regulatory uncertainty [S1].
- The company has no full-time employees as of 2025-12-31 and relies on contractors, with plans to expand workforce subject to capital availability [S1].
- The company has a history of losses, no revenue, and its independent auditor expressed substantial doubt about its ability to continue as a going concern [S1].
- The company’s CEO holds a controlling interest and significant voting power, which may limit influence of other shareholders [S1].
- The healthcare AI industry is highly competitive and rapidly evolving, with risks of technological obsolescence and regulatory challenges [S1].
- As of 2026-09-30, the company reported total assets of $7,824,000, all intangible assets, and current liabilities of $829,189, with zero current assets and no cash or equivalents reported [S2].
- Net income for the quarter ended 2026-09-30 was a loss of $58,108 [S2].
- Earnings per share basic and diluted were reported as zero for the periods ending 2026-06-30 and 2026-09-30 respectively [S2].
- The company’s liquidity ratios as of 2026-09-30 show a current ratio and cash ratio of zero due to zero current assets and liabilities of $829,189 [S2].
- Recent news about the company includes establishment of LataMed AI VE, C.A. to support Venezuelan telehealth operations, capital structure updates, attendance at HLTH Europe 2026, regulatory and deployment updates for telehealth platform in Venezuela, appointment of a COO, and initial launch of telehealth platform in April 2026 [N1][S1].
Generated 2026-11-13
- S1 | 2026-05-04 | 10-K/A
- S2 | 2026-11-13 | 10-Q
- N1 | 2026-11-13 | www.nasdaq.com | Cocoa Prices Climb as Ivory Coast Rains Disrupt Cocoa Supplies | https://www.nasdaq.com/articles/cocoa-prices-climb-ivory-coast-rains-disrupt-cocoa-supplies
- N2 | 2026-11-13 | www.nasdaq.com | Stocks Settle Lower on Nvidia Rout and Higher Crude and Bond Yields | https://www.nasdaq.com/articles/stocks-settle-lower-nvidia-rout-and-higher-crude-and-bond-yields
- N3 | 2026-11-13 | www.nasdaq.com | Stocks Pressured by Rising Bond Yields | https://www.nasdaq.com/articles/stocks-pressured-rising-bond-yields-2
- N4 | 2026-11-13 | www.nasdaq.com | PAVmed (PAVM) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/pavmed-pavm-q3-2026-earnings-call-transcript
- N5 | 2026-11-13 | www.nasdaq.com | Petrobras (PBR) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/petrobras-pbr-q3-2026-earnings-call-transcript
- N6 | 2026-11-13 | www.nasdaq.com | Gold Ticks Higher As Concerns Of Stagflation Emerge Amid Ongoing U.S.-Iran Faceoff | https://www.nasdaq.com/articles/gold-ticks-higher-concerns-stagflation-emerge-amid-ongoing-us-iran-faceoff
- N7 | 2026-11-13 | www.nasdaq.com | Aveanna Healthcare Q3 Revenue Rises 11.8%; Raises 2026 Financial Outlook | https://www.nasdaq.com/articles/aveanna-healthcare-q3-revenue-rises-118-raises-2026-financial-outlook
- N8 | 2026-11-13 | www.nasdaq.com | Coffee Prices Erase Early Gains as the Brazilian Real Tumbles | https://www.nasdaq.com/articles/coffee-prices-erase-early-gains-brazilian-real-tumbles
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


